Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check4 days agoChange DetectedVersion bump from v3.0.1 to v3.0.2; no substantive content changes detected. The removal of 'Back to Top' is a minor UI change.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as important references to drug safety and systemic sclerosis research. Notably, the term 'nintedanib' has been retained, while previous mentions of 'nintedanib esylate' and 'Scleroderma, Diffuse' have been removed.SummaryDifference7%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.